SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gets USFDA approval for Zolmitriptan Tablets

24 May 2016 Evaluate

Ajanta Pharma has received final approval of Zolmitriptan tablets (2.5mg, 5mg) from the U.S. Food and Drug Administration (FDA). Zolmitriptan is used in the acute treatment of migraine and is an equivalent generic version of Zomig1.

Zolmitriptan Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (U.S.FDA) has granted Ajanta Pharma 9 ANDA final approvals and 2 tentative approvals. Additional 15 ANDAs are under review with the FDA.

Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

Ajanta Pharma Share Price

3032.20 -48.00 (-1.56%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×